MedTrace Logo

Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia

NCT02040883 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-01-20

No results posted yet for this study

Summary

Efficacy and safety of Tandospirone combined with Atypical Antipsychotic drugs to Improve Cognitive function in Schizophrenia

Conditions

Interventions

DRUG

Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole

Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.

DRUG

Tandospirone

Tandospirone，30mg per day

Sponsors & Collaborators

  • Qingyun Yin

    lead OTHER_GOV

Principal Investigators

  • Qingyun Yin · Guangzhou Psychiatric Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02040883 on ClinicalTrials.gov